tenofovir disoproxil fumarate

FDA Drug Profile — tenofovir disoproxil fumarate, TENOFOVIR DISOPROXIL FUMARATE

tenofovir disoproxil fumarate is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand names including tenofovir disoproxil fumarate, TENOFOVIR DISOPROXIL FUMARATE. Available dosage forms: tablet, film coated, powder, tablet, tablet, coated.

Drug details

Generic Name
tenofovir disoproxil fumarate
Brand Names
tenofovir disoproxil fumarate, TENOFOVIR DISOPROXIL FUMARATE
Application Number
ANDA203232
Sponsor
Major Pharmaceuticals
NDC Codes
7
Dosage Forms
TABLET, FILM COATED, POWDER, TABLET, TABLET, COATED
Routes
ORAL
Active Ingredients
TENOFOVIR DISOPROXIL FUMARATE

Indications and Usage

1 INDICATIONS AND USAGE Tenofovir disoproxil fumarate is a nucleotide analog HIV-1 reverse transcriptase inhibitor and an HBV reverse transcriptase inhibitor and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 35 kg. ( 1.1 ) for the treatment of chronic hepatitis B in adults and pediatric patients 2 years and older weighing at least 35 kg. ( 1.2 ) 1.1 HIV-1 Infection Tenofovir disoproxil fumarate is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients 2 years of age and older weighing at least 35 kg. 1.2 Chronic Hepatitis B Tenofovir disoproxil fumarate is indicated for the treatment of chronic hepatitis B virus (HBV) in adults and pediatric patients 2 years of age and older weighing at least 35 kg.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.